NICE Recommends Advanced Kidney Cancer Treatment for NHS

The U.K.’s National Institute for Health and Care Excellence recommended that Eisai’s cancer drug lenvatinib be made available through the National Health Service for treatment of patients with advanced kidney cancer.

The institute recommended lenvatinib plus everolimus as an option for treating adults who have had one previous treatment with vascular endothelial growth factor (VEGF)-targeted therapy.

In a clinical trial, patients treated with lenvatinib along with everolimus lived approximately 10 months longer than those who took everolimus alone.